Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor-specific genetically engineered murine/human chimeric monoclonal antibody.

B A Brown, G L Davis, J Saltzgaber-Muller

    Cancer Research
    |July 1, 1987
    PubMed
    Summary

    Researchers created functional chimeric antibodies by fusing mouse and human gene segments. These engineered antibodies showed similar efficacy to original mouse antibodies, suggesting potential for improved clinical use in cancer therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Beta-Decay Half-Lives beyond ^{54}Ca: A Systematic Survey of Decay Properties Approaching the Neutron Dripline.

    Physical review letters·2026
    Same author

    Clarifying the N,Z=14 Shells near the Drip Lines from the Spectroscopy of ^{22}Si and ^{21}Al.

    Physical review letters·2026
    Same author

    Universal Effective Charges in the sd and fp Shells.

    Physical review letters·2025
    Same author

    Molecular identification of tapeworm infection in a bottlenose dolphin, <i>Tursiops</i> sp., in South Carolina, USA.

    Journal of helminthology·2025
    Same author

    Deformation and Collectivity in Doubly Magic ^{208}Pb.

    Physical review letters·2025
    Same author

    Measurement of the Isolated Nuclear Two-Photon Decay in ^{72}Ge.

    Physical review letters·2024

    Area of Science:

    • Immunology
    • Biotechnology
    • Oncology

    Background:

    • Murine monoclonal antibodies are effective cancer therapeutics but can elicit immune responses in patients.
    • Developing antibodies with reduced immunogenicity while retaining efficacy is crucial for cancer treatment.

    Purpose of the Study:

    • To engineer and characterize chimeric antibodies combining murine variable regions with human constant regions.
    • To evaluate the immunological properties and biodistribution of these chimeric antibodies compared to their parental murine counterparts.

    Main Methods:

    • Fusion of murine variable and human constant region exons to create chimeric immunoglobulin genes.
    • Cotransfection into murine myeloma cells for antibody production and secretion.
    • Purification of chimeric antibodies via affinity chromatography.

    Related Experiment Videos

  • Comparison of immunological properties (competitive binding, immunofluorescence, immunoprecipitation) and biodistribution in mice.

    • Main Results:

    • Functional chimeric antibodies were successfully produced and secreted.
    • Chimeric antibodies exhibited comparable immunological specificity and binding to parental murine antibodies (B6.2) against carcinoma cells.
    • Biodistribution studies in tumor-bearing mice showed identical patterns for both chimeric and murine antibodies.

    Conclusions:

    • Murine/human chimeric antibodies demonstrate equivalent efficacy to murine monoclonals.
    • Chimeric antibodies hold promise as clinical replacements for murine antibodies.
    • Potential benefits include improved immunological tolerance and enhanced pharmacological efficacy in cancer therapy.